Hawaii HB553 mandates coverage for biomarker testing in health insurance policies and mutual benefit societies starting January 1, 2026.

Hawaii HB553 requires individual or group health insurance policies and mutual benefit societies to cover biomarker testing for subscribers and members starting January 1, 2026. Biomarker testing includes analysis of tissue, blood, or other biospecimens to detect gene mutations, gene characteristics, and protein expression. Insurers and mutual benefit societies must provide written notice to policyholders and members about this coverage by December 31, 2026.

Hawaii HB553 mandates coverage for biomarker testing in health insurance policies and mutual benefit societies starting January 1, 2026.

Hawaii HB553 requires individual or group health insurance policies and mutual benefit societies to cover biomarker testing for subscribers and members starting January 1, 2026. Biomarker testing includes analysis of tissue, blood, or other biospecimens to detect gene mutations, gene characteristics, and protein expression. Insurers and mutual benefit societies must provide written notice to policyholders and members about this coverage by December 31, 2026.